Amendment: SEC Form F-4/A filed by Oncolytics Biotech Inc.
$ONCY
Biotechnology: Pharmaceutical Preparations
Health Care
Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/13/2025 | $7.00 | Buy | Lake Street |
| 10/6/2022 | $3.00 | Buy | Maxim Group |
VANCOUVER, British Columbia, Dec. 06, 2025 (GLOBE NEWSWIRE) -- USANewsGroup.com Market Intelligence Brief – The market is efficient... until it isn't. While the S&P 500 grinds higher on momentum, entire subsectors have been left behind, creating a massive disconnect between Operational Reality and Stock Price. They are quietly rotating into specific, overlooked pockets of value, from late-stage biotech to critical defense infrastructure, where the fundamentals have improved, but the valuation has not. We have identified five high-conviction anomalies. These are companies sitting at the intersection of imminent catalysts and historical undervaluation. Let's look at the data. The Patent C
VANCOUVER, British Columbia, Dec. 03, 2025 (GLOBE NEWSWIRE) -- USANewsGroup.com Market Intelligence Brief – Efficient Market Theory often fails in the small-cap sector. In this space, price discovery is slow. It lags behind the news. This creates a "valuation disconnect" where a company's fundamental reality has shifted but the ticker remains anchored to an old story. For the disciplined investor, this lag is the signal. The following report analyzes five specific case studies of this phenomenon. We look at an immunotherapy priced as if its clinical wins never happened, an FDA-cleared AI platform valued as a hardware vendor, a permitted developer priced as an explorer, a US uranium valid
VANCOUVER, British Columbia, Dec. 03, 2025 (GLOBE NEWSWIRE) -- USANewsGroup.com Market Intelligence Brief – Efficient Market Theory often fails in the small-cap sector. In this space, price discovery is slow. It lags behind the news. This creates a "valuation disconnect" where a company's fundamental reality has shifted but the ticker remains anchored to an old story. For the disciplined investor, this lag is the signal. The following report analyzes five specific case studies of this phenomenon. We look at an immunotherapy priced as if its clinical wins never happened, an FDA-cleared AI platform valued as a hardware vendor, a permitted developer priced as an explorer, a US uranium valid
F-4/A - ONCOLYTICS BIOTECH INC (0001129928) (Filer)
6-K - ONCOLYTICS BIOTECH INC (0001129928) (Filer)
6-K - ONCOLYTICS BIOTECH INC (0001129928) (Filer)
Lake Street initiated coverage of Oncolytics Biotech with a rating of Buy and set a new price target of $7.00
Maxim Group initiated coverage of Oncolytics Biotech with a rating of Buy and set a new price target of $3.00
H.C. Wainwright initiated coverage of Oncolytics Biotech with a rating of Buy and set a new price target of $15.00
Key opinion leader event and pancreatic cancer clinical data validate decision to engage with regulators on plans for a registration-enabling study New members of the management team bring expertise in progressing clinical programs and executing successful biotech transactions Translational data further elucidate pelareorep's mechanism of action and ability to prime the tumor microenvironment for treatment Commitment to limiting dilution evidenced by termination of At-the-Market and Equity Line of Credit facilities SAN DIEGO, Aug. 8, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareo
American Society of Clinical Oncology (ASCO) GI Symposium data underscores pelareorep's clinical benefit in anal and pancreatic cancers Pelareorep featured in Key Opinion Leader event on oncolytic immunotherapies in breast and pancreatic cancers Poster on pelareorep's stimulation of adaptive and innate immunity to be shared at ASCO Annual Meeting Conference call and webcast today at 4:30 p.m. ET to discuss Q1 results and clinical outlook SAN DIEGO, Calif. and CALGARY, AB, May 14, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today reported on highlights and financial results for the first qu
Conference call and webcast to take place on Wednesday, May 14, 2025, at 4:30 p.m. ET SAN DIEGO and CALGARY, AB, May 6, 2025 Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced that it will host a conference call and webcast on Wednesday, May 14, 2025, at 4:30 p.m. ET to discuss a corporate update and financial results for the first quarter of 2025. Conference Call & Webcast Date: Wednesday, May 14, 2025Time: 4:30 p.m. ETDial In – North American Toll-Free: (888) 510-2154Dial In – Interna
Equity Insider News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, July 8, 2025 /PRNewswire/ -- Equity Insider News Commentary – As cancer rates climb and drug costs continue to soar, pressure is mounting on the private sector to drive innovation. Now, cancer experts are alarmed over a "gut wrenching" plan from the U.S. government to cut nearly 40% of National Cancer Institute funding, even as the price of oncology treatments pushes new limits—raising urgent concerns about access and affordability. In this shifting landscape, investors are turning their attention to a new wave of biotechs and specialty care providers developing breakthrough therapies and smarter care mo
USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 30, 2025 /PRNewswire/ -- USA News Group News Commentary – The oncology landscape is being pulled in two directions. On one hand, U.S. cancer death rates continue to decline. On the other, global cases are expected to rise sharply—while early-onset diagnoses in younger patients are climbing at a troubling pace. At the same time, proposed federal budget cuts threaten to slash funding for the National Cancer Institute by up to 40%, raising concerns about the future of publicly funded research. With public resources under pressure, much of the innovation burden is shifting to the private sector, where a
SAN DIEGO and CALGARY, Alberta, June 30, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced the appointment of Andrew Aromando as Chief Business Officer. Mr. Aromando most recently served as Chief Operating Officer at Ambrx Biopharma, where his contributions were instrumental in the $2 billion acquisition of the San Diego-based biotech by Johnson & Johnson. In his role at Oncolytics, Mr. Aromando will be responsible for leading global business development. He will a